Dose setting test of insulin secretion inhibitor.
Not Applicable
- Conditions
- Visceral obesity with hyperinsulinemia.
- Registration Number
- JPRN-jRCTs071200028
- Lead Sponsor
- Moritake Higa
- Brief Summary
75mg of diazoxide was approved for visceral fat obesity patients without overt diabetes mellitus.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 7
Inclusion Criteria
1. Visiting Tomishiro Central Hospital at the Diabetes and Lifestyle Disease Center.
2. Written informed consent.
3. Waist length is more than 85cm of male or 90cm of female.
Exclusion Criteria
Diabetes mellitus. Pt of Heart, Lung, Liver, Kidney or GI disease. Subjects of pregnancy or of allergy against diazoxide.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method